CIMZIA® (certolizumab pegol)
is indicated for adults with:
MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA)
ACTIVE PSORIATIC ARTHRITIS (PsA)
ACTIVE ANKYLOSING SPONDYLITIS (AS)
MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD) IF RESPONSE TO CONVENTIONAL THERAPY IS INADEQUATE
Moderate to severe plaque psoriasis (PSO)
who are candidates for systemic therapy or phototherapy
axSpA
ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)
WITH OBJECTIVE SIGNS OF INFLAMMATION
CIMZIA formulation options align with patient needs.
